A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir/Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
Latest Information Update: 30 Apr 2021
Price :
$35 *
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 22 Apr 2021 Planned initiation date changed from 1 Nov 2020 to 1 May 2021.
- 22 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Sep 2020 Planned End Date changed from 1 Jul 2021 to 1 Nov 2021.